These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23686260)

  • 1. HMGA2 and high-grade serous ovarian carcinoma.
    Wu J; Wei JJ
    J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.
    Wu J; Liu Z; Shao C; Gong Y; Hernando E; Lee P; Narita M; Muller W; Liu J; Wei JJ
    Cancer Res; 2011 Jan; 71(2):349-59. PubMed ID: 21224353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
    Wu J; Lai M; Shao C; Wang J; Wei JJ
    Oncol Rep; 2015 Sep; 34(3):1494-502. PubMed ID: 26165228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.
    McMillen BD; Aponte MM; Liu Z; Helenowski IB; Scholtens DM; Buttin BM; Wei JJ
    Mod Pathol; 2012 Dec; 25(12):1644-53. PubMed ID: 22790015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].
    Yang J; Zhang Q; Dong JQ; Chang XH; He XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):749-54. PubMed ID: 23073586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
    Liu Z; Liu J; Segura MF; Shao C; Lee P; Gong Y; Hernando E; Wei JJ
    J Pathol; 2012 Oct; 228(2):204-15. PubMed ID: 22322863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
    Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
    Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shortening of the 3' untranslated region: an important mechanism leading to overexpression of HMGA2 in serous ovarian cancer.
    He X; Yang J; Zhang Q; Cui H; Zhang Y
    Chin Med J (Engl); 2014; 127(3):494-9. PubMed ID: 24451956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2.
    Tian X; Song J; Zhang X; Yan M; Wang S; Wang Y; Xu L; Zhao L; Wei JJ; Shao C; Kong B; Liu Z
    Cell Death Dis; 2020 Mar; 11(3):167. PubMed ID: 32127525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
    Xing F; Song Z; He Y
    Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
    Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
    Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
    Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
    Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
    Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia.
    Unachukwu U; Chada K; D'Armiento J
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
    Drumond-Bock AL; Bieniasz M
    Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
    Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
    Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.